Rhythm Pharmaceuticals

Rare genetic obesity / MC4R pathway

RYTM · Nasdaq · United States

Share price · RYTM

$119.04+3.79 (+3.29%) 3M

close as of 2026-11-18 · 24h delayed · vol 2.0M (1.3x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when RYTM's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 17 Nov 2026+8.5%
  2. 4 Nov 2026+28.0%
  3. 3 Nov 2026-7.5%
  4. 29 May 2026-5.0%
  5. 11 May 2026-7.2%

    Nothing announced by RYTM that day or the session before.

  6. 5 May 2026+7.9%
  7. 11 Dec 2025+12.3%

Share of unusual movement by asset

For each asset, the share of RYTM's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
setmelanotide (Imcivree)
events and moves
1619%
bivamelagon
events and moves
2shown from 8 days
RM-718
events and moves
1shown from 8 days
Assets with fewer than 8 event days, together—2%
Other company news (earnings, financing, releases naming no asset)—37%
Sessions with no dated event—42%

Assets

(3 total)
3Total Assets
1Approved
0Phase 3 / Filed
2Phase 1–2 / Early
4Diseases
Quick filter:
Showing 3 of 3 assets
Target & Modality
setmelanotide(Imcivree)
Approved
MC4RPeptide
ObesityBardet-Biedl SyndromeHypothalamic ObesityPrader-Willi Syndrome
Phase 2
MC4RSmall molecule
Hypothalamic Obesity
Phase 1/2
MC4RPeptide
Obesity

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
March 2027 (1)
setmelanotide · ImcivreePhase 3Hypothalamic Obesity, Multiple Pituitary Hormone Deficiency Genetic Form, Septo-Optic Dysplasia, Optic Nerve Hypoplasia …
Est. primary completion 2027-03-13 · NCT06760546 · CT.gov ↗
What to watch
May 2027 (1)
RM-718Phase 1/2Hypothalamic Obesity, Prader-Willi Syndrome, PWS
Est. primary completion 2027-05-07 · NCT06239116 · CT.gov ↗
What to watch
2028 (1)
April 2028 (1)
bivamelagonPhase 2Hypothalamic Obesity
Est. primary completion 2028-04-15 · NCT07156578 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(5)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

22 September 2026ApprovalsetmelanotideHealth Canada approves IMCIVREE for acquired hypothalamic obesity
CA, Health Canada · Rhythm Pharmaceuticals, Inc. · Source ↗
24 August 2026ApprovalsetmelanotideJapan MHLW approves IMCIVREE for acquired hypothalamic obesity
JP, MHLW · Source ↗
11 August 2026ApprovalsetmelanotideMHRA expands Imcivree authorisation to acquired hypothalamic obesity
UK, MHRA · Source ↗
4 August 2026Topline resultRM-718Preliminary Phase 2 data for RM-718 in acquired hypothalamic obesity
Rhythm Pharmaceuticals · Source ↗
16 March 2026Topline resultsetmelanotidePhase 3 EMANATE: none of the four substudies met its primary endpoint

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$92M$52M$40M+ $281M short-term inv.$41M-$3.1M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$71M$43M$66M+ $265M short-term inv.$49M-$9.2M operating cash flowreport ↗
2026-Q1—$42M$62M+ $278M short-term inv.$56M-$44M operating cash flowreport ↗
2025-Q3—$46M$52M+ $364M short-term inv.$53M-$27M operating cash flowreport ↗
2025-Q2—$42M$136M+ $155M short-term inv.$47M-$23M operating cash flowreport ↗
2025-Q1—$37M$106M+ $208M short-term inv.$50M-$40M operating cash flowreport ↗
2024-Q3—$38M$48M+ $251M short-term inv.$44M-$25M operating cash flowreport ↗
2024-Q2$29M$30M$162M+ $157M short-term inv.$32M-$29M operating cash flowreport ↗
2024-Q1$26M$129M$53M+ $148M short-term inv.$141M-$41M operating cash flowreport ↗
2023-Q3$23M$34M$65M+ $235M short-term inv.$44M-$29M operating cash flowreport ↗
2023-Q2$19M$34M$116M+ $138M short-term inv.$47M-$41M operating cash flowreport ↗
2023-Q1$11M$38M$110M+ $185M short-term inv.$52M-$36M operating cash flowreport ↗
2022-Q3$4.3M$21M$185M+ $163M short-term inv.$41M-$47M operating cash flowreport ↗
2022-Q2$9.1M$31M$113M+ $122M short-term inv.$45M-$39M operating cash flowreport ↗
2022-Q1$1.5M$33M$79M+ $162M short-term inv.$53M-$54M operating cash flowreport ↗
2021-Q3$1.0M$28M$92M+ $236M short-term inv.$35M-$40M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY—$167M$54M+ $335M short-term inv.$49M-$116M operating cash flowreport ↗

Rhythm Pharmaceuticals reported fourth-quarter IMCIVREE net product revenue of $57.3M and full-year 2025 net product revenue of $194.8M, versus $41.8M and $130.1M, respectively, in 2024. R&D expense was $167.34M, down 29.7% YoY, and the company ended 2025 with cash and equivalents of $54.3M, or approximately $388.9M including short-term investments. Full-year net loss was $196.54M; the fourth-quarter net loss attributable to common stockholders was $48.8M, or $(0.73) per basic and diluted share.

Rhythm guided to 2026 non-GAAP operating expenses of approximately $385M to $415M and expects its current cash position to fund planned operations for at least 24 months. Key clinical updates include the March 20, 2026 PDUFA goal date for setmelanotide in acquired hypothalamic obesity, a positive end-of-Phase-2 FDA meeting for bivamelagon with persistent BMI reductions at six and nine months, and expected March 2026 topline data from the Japanese cohort of the setmelanotide Phase 3 trial in acquired hypothalamic obesity and the Phase 3 EMANATE trial. The company also reported positive preliminary results from its exploratory Phase 2 trial of setmelanotide in Prader-Willi syndrome.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY—$238M$89M+ $231M short-term inv.$65M-$114M operating cash flowreport ↗
2023-FY$77M$135M$60M+ $216M short-term inv.$46M-$136M operating cash flowreport ↗
2022-FY$24M$109M$128M+ $206M short-term inv.$45M-$173M operating cash flowreport ↗
2021-FY$3.1M$104M$59M+ $236M short-term inv.$17M-$146M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 50 sales ($37.1M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-17JEAN CHRISTOPHE · directorOption exercise10,000$34.89$349KForm 4
2026-11-17JEAN CHRISTOPHE · directorOpen-market sale5,000$106.81$534KForm 4
2026-11-17JEAN CHRISTOPHE · directorOpen-market sale2,500$110.00$275KForm 4
2026-11-17JEAN CHRISTOPHE · directorOpen-market sale2,500$115.00$288KForm 4
2026-11-17JEAN CHRISTOPHE · directorOption exercise (derivative)10,000——Form 4
2026-09-14Meeker David P · director, President and CEOOption exercise50,000$6.05$303KForm 4
2026-09-14Meeker David P · director, President and CEOOpen-market sale6,439$101.75$655KForm 4
2026-09-14Meeker David P · director, President and CEOOpen-market sale30,746$102.35$3.1MForm 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 284 reporting institutions held 73.6M shares ($6.2B, 106.1% of shares outstanding).

#InstitutionSharesValue
1RA CAPITAL MANAGEMENT, L.P.6,666,837$579.8M
2BlackRock, Inc.6,237,151$542.4M
3BAKER BROS. ADVISORS LP5,604,483$487.4M
4PRIMECAP MANAGEMENT CO/CA/3,417,509$297.2M
5VANGUARD PORTFOLIO MANAGEMENT LLC3,040,718$264.5M
6VANGUARD CAPITAL MANAGEMENT LLC2,967,825$258.1M
7PERCEPTIVE ADVISORS LLC2,373,795$206.4M
8STATE STREET CORP2,271,851$197.6M
9GOLDMAN SACHS GROUP INC1,965,432$170.9M
10WESTFIELD CAPITAL MANAGEMENT CO LP1,929,123$167.8M
11FMR LLC1,689,671$147.0M
12Polar Capital Holdings Plc1,615,586$140.5M
13CITADEL ADVISORS LLC1,418,619$123.4M
14GEODE CAPITAL MANAGEMENT, LLC1,416,269$123.2M
15JPMORGAN CHASE & CO1,553,644$120.0M